Literature DB >> 15654275

Second malignancy after treatment of pediatric Hodgkin disease.

Han-Ming Joseph Lin1, Michael A Teitell.   

Abstract

Although treatment of pediatric Hodgkin disease has become highly effective over the past 40 years, a number of patients have developed concerning late effects, such as secondary malignancies. These cancers may occur years to decades after remission and arise in the breast, thyroid, gastrointestinal tract, lung, skin, urogenital tract, and brain. There is also an increased risk of leukemia and non-Hodgkin lymphoma. Etiology and risk factors for each cancer type vary but often include certain chemotherapy agents and radiation dosages. Survivorship also varies but is often poor. The authors examined retrospective analyses of these secondary malignancies and present a summary of these findings. The information may allow clinicians to better monitor childhood Hodgkin disease survivors and reduce mortality.

Entities:  

Mesh:

Year:  2005        PMID: 15654275     DOI: 10.1097/01.mph.0000150740.80690.d4

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  15 in total

1.  Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy.

Authors:  Rebecca M Howell; Sarah B Scarboro; Phillip J Taddei; Sunil Krishnan; Stephen F Kry; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  Effect of organ size and position on out-of-field dose distributions during radiation therapy.

Authors:  Sarah B Scarboro; Marilyn Stovall; Allen White; Susan A Smith; Derek Yaldo; Stephen F Kry; Rebecca M Howell
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

Review 3.  Regulation of cell differentiation by the DNA damage response.

Authors:  Mara H Sherman; Craig H Bassing; Michael A Teitell
Journal:  Trends Cell Biol       Date:  2011-02-25       Impact factor: 20.808

4.  Stimulation of the hypoxia pathway modulates chemotherapy resistance in Hodgkin's lymphoma cells.

Authors:  Stefanie Kewitz; Lars Kurch; Ines Volkmer; Martin S Staege
Journal:  Tumour Biol       Date:  2015-12-30

5.  Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.

Authors:  Chi Lin; Sarah S Donaldson; Jane L Meza; James R Anderson; Elizabeth R Lyden; Christopher K Brown; Karen Morano; Fran Laurie; Carola A Arndt; Charles A Enke; John C Breneman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-04       Impact factor: 7.038

Review 6.  Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies.

Authors:  Sebastian Zahnreich; Heinz Schmidberger
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 7.  Treatment of pediatric hodgkin lymphoma.

Authors:  Michael R Olson; Sarah S Donaldson
Journal:  Curr Treat Options Oncol       Date:  2008-05-07

Review 8.  Adult life after surviving lymphoma in childhood.

Authors:  Nicolas X von der Weid
Journal:  Support Care Cancer       Date:  2008-01-15       Impact factor: 3.603

Review 9.  Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents--a single institution's experience and a review of the literature.

Authors:  Florian Sterzing; Eva M Stoiber; Simeon Nill; Harald Bauer; Peter Huber; Jürgen Debus; Marc W Münter
Journal:  Radiat Oncol       Date:  2009-09-23       Impact factor: 3.481

10.  Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.

Authors:  Stefanie Kewitz; Martin S Staege
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.